Boothbay Fund Management, LLC Chimerix Inc Transaction History

Boothbay Fund Management, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$1.34 - $5.34 $44,059 - $175,579	-32,880 Reduced 38.7%	52,074 $108,000
Q4 2021 Feb 14, 2022	BUY	$5.23 - $7.18 $25,548 - $35,074	4,885 Added 6.1%	84,954 $546,000
Q3 2021 Nov 15, 2021	SELL	$5.94 - $8.75 $600,219 - $884,161	-101,047 Reduced 55.79%	80,069 $496,000
Q2 2021 Aug 16, 2021	SELL	$7.54 - $9.79 $14,484 - $18,806	-1,921 Reduced 1.05%	181,116 $1.45 Million
Q1 2021 May 17, 2021	BUY	$4.76 - $11.25 $214,795 - $507,656	45,125 Added 32.72%	183,037 $1.76 Million
Q4 2020 Feb 12, 2021	SELL	$2.43 - $5.42 $33,444 - $74,595	-13,763 Reduced 9.07%	137,912 $666,000
Q3 2020 Nov 16, 2020	BUY	$2.3 - $3.72 $348,852 - $564,231	151,675 New	151,675 $378,000
Q2 2020 Aug 14, 2020	SELL	$1.33 - $3.63 $44,161 - $120,530	-33,204 Closed	0 $0
Q4 2019 Feb 14, 2020	SELL	$1.3 - $2.72 $197,944 - $414,160	-152,265 Reduced 82.1%	33,204 $67,000
Q3 2019 Nov 14, 2019	SELL	$1.93 - $4.21 $5,977 - $13,038	-3,097 Reduced 1.64%	185,469 $436,000
Q2 2019 Aug 14, 2019	BUY	$2.05 - $4.32 $386,560 - $814,605	188,566 New	188,566 $815,000

36.8M

72.2K

169K

Ticker CMRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 87,622,896
Market Cap $85M
Description
Chimerix, Inc., a biopharmaceutical company, develops medicines to enhance the lives of patients living with serious diseases. The company's approved product is TEMBEXA (brincidofovir), a lipid conjugate through inhibition of viral DNA synthesis that is developed as a medical countermeasure for smallpox. Its clinical stage development programs i...

Get notified when there are updates to the investment portfolio of Boothbay Fund Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Boothbay Fund Management, LLC with notifications on news.